Progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma

被引:2
|
作者
Liu, Tong [1 ]
Meng, Guorui [1 ]
Ma, Shihui [1 ]
You, Junqi [1 ]
Yu, Liang [1 ]
He, Risheng [1 ]
Zhao, Xudong [1 ]
Cui, Yunfu [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Hepatopancreatobiliary Surg, Harbin, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2024年 / 15卷
关键词
hepatocellular carcinoma; immune checkpoint inhibitors; immunotherapy; tumor immune microenvironment; review; OPEN-LABEL; INFUSION CHEMOTHERAPY; PLUS; MULTICENTER; BEVACIZUMAB; SINTILIMAB; LENVATINIB; EFFICACY; THERAPY; SAFETY;
D O I
10.3389/fimmu.2024.1455716
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Among primary liver cancers, hepatocellular carcinoma is the most common pathological type. Its onset is insidious, and most patients have no obvious discomfort in the early stage, so it is found late, and the opportunity for surgical radical treatment is lost, resulting in a poor prognosis. With the introduction of molecular-targeted drugs represented by sorafenib, patients with middle- and late-stage liver cancer have regained the light of day. However, their therapeutic efficacy is relatively low due to the limited target of drug action, toxic side effects, and other reasons. At this time, the emergence of immunotherapy represented by immune checkpoint inhibitors (ICIs) well breaks this embarrassing situation, which mainly achieves the anti-tumor purpose by improving the tumor immune microenvironment. Currently, ICI monotherapy, as well as combination therapy, has been widely used in the clinic, further prolonging the survival of patients with advanced hepatocellular carcinoma. This article reviews the development of monotherapy and combination therapy for ICIs in advanced hepatocellular carcinoma and the latest research progress.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] Immune checkpoint inhibitors in the treatment of hepatocellular carcinoma
    Akbulut, Zeynep
    Aru, Basak
    Aydin, Furkan
    Demirel, Gulderen Yanikkaya
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [22] Liver Transplantation for Hepatocellular Carcinoma in the Era of Immune Checkpoint Inhibitors
    De Stefano, Nicola
    Patrono, Damiano
    Colli, Fabio
    Rizza, Giorgia
    Paraluppi, Gianluca
    Romagnoli, Renato
    CANCERS, 2024, 16 (13)
  • [23] Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma
    Liu, Ziyu
    Lin, Yan
    Zhang, Jinyan
    Zhang, Yumei
    Li, Yongqiang
    Liu, Zhihui
    Li, Qian
    Luo, Ming
    Liang, Rong
    Ye, Jiazhou
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (01)
  • [24] Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma
    Yonemoto, Takuya
    Ogasawara, Sadahisa
    Kanogawa, Naoya
    Miwa, Chihiro
    Fujiya, Makoto
    Tsuchiya, Takahiro
    Sawada, Midori
    Akatsuka, Teppei
    Izai, Ryo
    Yumita, Sae
    Nakagawa, Miyuki
    Okubo, Tomomi
    Koroki, Keisuke
    Inoue, Masanori
    Nakamura, Masato
    Kondo, Takayuki
    Nakamoto, Shingo
    Itokawa, Norio
    Atsukawa, Masanori
    Itobayashi, Ei
    Moriguchi, Michihisa
    Kato, Naoya
    HEPATOLOGY RESEARCH, 2025,
  • [25] Enlighting the Shadow for Advanced Hepatocellular Carcinoma: Immunotherapy with Immune Checkpoint Inhibitors
    Sahin B.
    Journal of Gastrointestinal Cancer, 2017, 48 (3) : 288 - 290
  • [26] The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma
    Wang, Yun
    Jiang, Man
    Zhu, Jingjuan
    Qu, Jialin
    Qin, Kang
    Zhao, Deze
    Wang, Li
    Dong, Lina
    Zhang, Xiaochun
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 132
  • [27] Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
    Personeni, Nicola
    Pressiani, Tiziana
    D'Alessio, Antonio
    Prete, Maria Giuseppina
    Bozzarelli, Silvia
    Terracciano, Luigi
    Dal Buono, Arianna
    Capogreco, Antonio
    Aghemo, Alessio
    Lleo, Ana
    Lutman, Romano Fabio
    Roncalli, Massimo
    Giordano, Laura
    Santoro, Armando
    Di Tommaso, Luca
    Rimassa, Lorenza
    CANCERS, 2021, 13 (22)
  • [28] Hepatic arterial infusion chemotherapy combined with immune checkpoint inhibitors and molecular targeted therapies for advanced infiltrative hepatocellular carcinoma: a single-center experience
    Wang, Zizhuo
    Song, Songlin
    Zhang, Lijie
    Yang, Tingting
    Yao, Wei
    Liang, Bin
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [29] Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    Dyhl-Polk, Anne
    Mikkelsen, Marta Kramer
    Ladekarl, Morten
    Nielsen, Dorte Lisbet
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (12)
  • [30] Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Opportunities and Challenges
    Liu, Xiufeng
    Qin, Shukui
    ONCOLOGIST, 2019, 24 : S3 - S10